VaxigripTetra Sospensione iniettabile in siringa pre-riempita

Land: Schweiz

Sprache: Italienisch

Quelle: Swissmedic (Swiss Agency for Therapeutic Products)

Wirkstoff:

haemagglutininum influenzae di tipo A (H1N1) (ceppo del Virus A/Michigan/45/2015 (H1N1)-like: reassortant virus NYMC X-275), haemagglutininum influenzae A (H3N2) (ceppo del Virus A/Singapore/INFIMH-16-0019/2016 (H3N2)-come: reassortant virus IVR-186), haemagglutininum influenzae B (Virus del ceppo B/Colorado/06/2017-come: reassortant virus NYMC BX-69A derivata da B/Veneto/15/2016 (Victoria lignaggio))

Verfügbar ab:

Sanofi-Aventis (Suisse) SA

ATC-Code:

J07BB02

INN (Internationale Bezeichnung):

haemagglutininum influenzae A (H1N1) (Virus strain A/Michigan/45/2015 (H1N1)-like: reassortant virus NYMC X-275), haemagglutinin

Darreichungsform:

Sospensione iniettabile in siringa pre-riempita

Zusammensetzung:

haemagglutininum influenzae A (H1N1) (Virus souche A/Michigan/45/2015 (H1N1)-like: reassortant virus NYMC X-275) 15 µg, haemagglutininum influenzae A (H3N2) (Virus souche A/Singapore/INFIMH-16-0019/2016 (H3N2)-like: reassortant virus IVR-186) 15 µg, haemagglutininum influenzae B (Virus souche B/Colorado/06/2017-like: reassortant virus NYMC BX-69A derived from B/Maryland/15/2016 (Victoria lineage)) 15 µg, haemagglutininum influenzae B (Virus souche B/Phuket/3073/2013-like: reassortant virus Wild type derived from B/Phuket/3073/2013 (Yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum.

Therapiegruppe:

Impfstoffe

Therapiebereich:

Immunizzazione attiva contro l'influenza, come già nel 6 ° mese

Berechtigungsdatum:

2018-06-12